Pin your most used calculators here by clicking the star in the dropdown.
MammaPrint Interpreter
Clinical Context & Background
MammaPrint analyzes 70 genes to determine the risk of breast cancer recurrence. The MINDACT trial demonstrated its utility in de-escalating chemotherapy in patients who are clinically high risk but genomically low risk.
Formula Logic
Binary classification: Low Risk vs High Risk.Reference Data
| Result | 5-Year DMFS (No Chemo) | Recommendation |
|---|---|---|
| Low Risk | > 95% | Chemotherapy can typically be omitted (MINDACT). |
| High Risk | < 90% | Chemotherapy recommended. |
Evidence-based oncology decision support. Verify with clinical guidelines.